Neuraxis (NRXS) Current Assets (2022 - 2025)
Neuraxis (NRXS) posted Current Assets of $5.7 million for Q4 2025, up 14.94% sequentially from $5.0 million in Q3 2025, and up 34.39% YoY from $4.3 million in Q4 2024.
Neuraxis (NRXS) Current Assets (2022 - 2025) Analysis & Trends
Neuraxis has reported Current Assets for 4 years, with the latest figure at $5.7 million in Q4 2025.
- Quarterly Current Assets rose 34.39% year-over-year to $5.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.7 million (up 34.39% YoY) and the FY2025 annual result came in at $5.7 million, up 34.39% from the prior year.
- Current Assets rose to $5.7 million in Q4 2025 per NRXS's latest filing, from $5.0 million in the prior quarter.
- Over five years, Current Assets peaked at $6.6 million in Q2 2025 and troughed at $242610.0 in Q4 2023.
- A 4-year average of $2.4 million and a median of $1.5 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2024: Current Assets tumbled 49.13% in 2023, then jumped 1658.45% in 2024.
- Over 4 years, Current Assets stood at $476957.0 in 2022, then slumped by 49.13% to $242610.0 in 2023, then surged by 1658.45% to $4.3 million in 2024, then jumped by 34.39% to $5.7 million in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $5.7 million, $5.0 million, and $6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.73 Mn |
| Sep 30, 2025 | 4.99 Mn |
| Jun 30, 2025 | 6.62 Mn |
| Mar 31, 2025 | 2.54 Mn |
| Dec 31, 2024 | 4.27 Mn |
| Sep 30, 2024 | 631,842.00 |
| Jun 30, 2024 | 2.11 Mn |
| Mar 31, 2024 | 407,834.00 |
| Dec 31, 2023 | 242,610.00 |
| Sep 30, 2023 | 966,854.00 |
| Jun 30, 2023 | 354,148.00 |
| Dec 31, 2022 | 476,957.00 |